Cadila Pharma has recently launched the world's first aqueous formulation of cholecalciferol for vitamin D deficiency. This innovative product offers superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to traditional oil-based cholecalciferol preparations available in the market.
The aqueous cholecalciferol injection provides a unique solution with a rapid correction of vitamin D deficiency in a shorter period. It enhances the efficacy of treatment and ensures a painless and easy administration process, marking a significant advancement in patient care.
This novel formulation demonstrates significant improvements in the drug's pharmacokinetic and pharmacodynamic properties, outperforming conventional oil-based cholecalciferol preparations.
Patients can now benefit from a swift correction of vitamin D deficiency quickly, addressing a critical need for expedited treatment outcomes in many major illnesses. The injection is designed for ease of use, providing a painless patient experience and promoting better compliance with treatment regimens.
Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals, stated, "Our commitment to innovation and patient-centric research to bridge the gap in areas of unmet medical need has driven the development of this groundbreaking aqueous cholecalciferol injection. We believe this advancement will redefine the landscape of Vitamin D deficiency treatment and ensure better treatment outcomes."
Dr. Vijayesh Gupta, COO- BSBU, Cadila Pharmaceuticals, added, "With the launch of the world's first aqueous Vitamin D injection, Cadila Pharmaceuticals reaffirms its dedication to providing cutting-edge healthcare solutions. We anticipate this innovation will help clinicians better design their treatment protocols for Vitamin D deficient patients, and many patients will benefit from the next generation, the world's first aqueous injectable Vitamin D."
, CDSCO.jpg)
.jpg)